NAP, a Femtomolar-Acting Peptide, Protects the Brain Against Ischemic Injury by Reducing Apoptotic Death
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background and Purpose — We sought to determine the cerebroprotective potential of NAP, a synthetic octapeptide related to vasoactive intestinal peptide. Activity-dependent neuroprotective protein mediates some of the protective effects of vasoactive intestinal peptide. The neuroprotective NAP sequence is derived from activity-dependent neuroprotective protein. Methods — Spontaneously hypertensive rats underwent permanent middle cerebral artery occlusion by craniotomy and electrocoagulation. After dose-response and time-course experiments, the animals were injected with NAP (3 μg/kg) or vehicle intravenously 1 hour after stroke onset. Another group of rats was injected with the d -amino acid isomer of NAP (D-NAP) and served as a negative control. Rats were examined for motor and behavioral deficits 24 hours to 30 days later, and infarct volumes were determined. The effect of NAP administration on apoptotic death was determined by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) and caspase-3 stainings. Results — NAP significantly reduced motor disability and infarct volumes compared with vehicle or D-NAP when tested at 24 hours after stroke onset (9.67±1.4% versus 17.04±1.18% and 19.19±1.9% of hemispheric volume, respectively; P <0.05). NAP given 4 but not 6 hours after permanent middle cerebral artery occlusion still conferred significant neuroprotection (infarct volume 10.9±3.9% of hemispheric volume; P <0.05 versus vehicle). Long-term studies demonstrated that infarct volumes and disability scores remained significantly lower after 30 days in NAP-treated animals. NAP significantly reduced the number of apoptotic cells. Conclusions — Our results indicate that the durable cerebroprotection by NAP involves antiapoptotic mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bederson, J. B., Pitts, L. H., Tsuji, M., Nishimura, M. C., Davis, R. L., & Bartkowski, H. (1986) · Stroke · doi:10.1161/01.str.17.3.472 · Cited by 2,681
Tumor Necrosis Factor-α: A Mediator of Focal Ischemic Brain Injury
Barone, F. C., Arvin, B., White, R. F., Miller, A., Webb, C. L., Willette, R. N., Lysko, P. G., & Feuerstein, G. Z. (1997) · Stroke · doi:10.1161/01.str.28.6.1233 · Cited by 863
Cloning and Characterization of the Human Activity-dependent Neuroprotective Protein
Zamostiano, R., Pinhasov, A., Gelber, E., Steingart, R. A., Seroussi, E., Giladi, E., Bassan, M., Wollman, Y., Eyre, H. J., Mulley, J. C., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007416200 · Cited by 251
Self-citation
Cited by
Activity-dependent neuroprotective protein: a novel gene essential for brain formation
Pinhasov, A., Mandel, S., Torchinsky, A., Giladi, E., Pittel, Z., Goldsweig, A. M., Servoss, S. J., Brenneman, D. E., & Gozes, I. (2003) · Developmental Brain Research · doi:10.1016/s0165-3806(03)00162-7 · Cited by 239
Self-citationActivity-Dependent Neuroprotective Protein Modulates Its Own Gene Expression
Aboonq, M. S., Vasiliou, S. A., Haddley, K., Quinn, J. P., & Bubb, V. J. (2012) · Journal of Molecular Neuroscience · doi:10.1007/s12031-011-9562-y · Cited by 23
Magrì, B., D'Amico, A. G., Maugeri, G., Morello, G., La Cognata, V., Saccone, S., Federico, C., Cavallaro, S., & D'Agata, V. (2023) · Neuropeptides · doi:10.1016/j.npep.2023.102386 · Cited by 3
Metadata
- Authors
- Leker, R. R., Teichner, A., Grigoriadis, N., Ovadia, H., Brenneman, D. E., Fridkin, M., Giladi, E., Romano, J., & Gozes, I.
- Venue
- Stroke
- Published
- 2002-04
- Volume
- 33
- Issue
- 4
- Pages
- 1085-1092
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W2125063109
- Cited by
- 116
- References
- 3
- FWCI
- 4.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.